Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting
Links shared publicly online about this topic.
- 670total visits
Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting
View full resource at eurekalert.org
Tags: Sexual Health, Depression, Antidepressant, Major Depression, Disease and Condition, Sex and Intimacy, Sexual Dysfunction
Most Recently Shared on December 8, 2010 at 3:07 pm By:
Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting: ( BioCom Partners ) Eut... http://bit.ly/hZ6XV5
Euthymics Presents Phase II Data For EB-1010 In Major Depression At ACNP Annual Meeting - Health News - redOrbit
redorbit.com — “Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.” View full resource at redorbit.com
Most Recently Shared on December 9, 2010 at 3:08 am By:
Euthymics Presents Phase II Data For EB-1010 In Major Depression At ACNP Annual Meeting: Data among the first po... http://bit.ly/hEniTV
Advertisement
